EI
HEPA

EAM Investors’s Hepion Pharmaceuticals HEPA Stock Holding History

EAM Investors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed -$3.4M – 337
2016
Q4 		$3.4M Buy
+1
New +$1.01M 0.45% 54
2015
Q4 		– Sell
-1
Closed -$3.11M – 332
2015
Q3 		$3.11M Buy
+1
New +$2.36M 0.49% 50

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

EAM Investors's HEPA Position: Q1 2017 in Review

EAM Investors sold out of Hepion Pharmaceuticals (HEPA) in Q1 2017, closing a stake of 1 share — an estimated $3.4M sold.

EAM Investors first reported a position in HEPA in Q3 2015 and held it in 2 quarters. The position peaked at $3.4M in Q4 2016. 3 funds tracked by Wall St. Rank hold HEPA as of Q1 2017.

  • EAM Investors reported no remaining Hepion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • EAM Investors sold 1 Hepion Pharmaceuticals share in Q1 2017, an estimated $3.4M.
  • EAM Investors first reported a position in Hepion Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • EAM Investors's Hepion Pharmaceuticals position peaked at $3.4M in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2017.

Based on EAM Investors's 13F filing for Q1 2017, filed 10 May 2017.